{"groups":[{"description":"MLN8237, 50 mg, taken by mouth twice daily on Days 1-7. One cycle is 3 weeks long (21 days). CT or MRI imaging for response every other cycle (every 6 weeks). Treatment may continue until disease progression or adverse effects prohibit further therapy.","id":"FG000","title":"MLN8237"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible: wrong primary"},{"reasons":[{"groupId":"FG000","numSubjects":"1"}],"type":"Ineligible: inadequate pathology"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"23"}],"type":"STARTED"},{"achievements":[{"comment":"Eligible and treated patients.","groupId":"FG000","numSubjects":"21"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"recruitmentDetails":"The study was activated on 8/6/2012 and closed to accrual on 6/3/2013."}